Emmaus Life Sciences, Inc. (EMMA): Depreciation & Amortization
$39.0K
Year ended 2025-12-31
$59.0K
Trailing 12 months to 2026-06-30
-9.7%
3-year compound annual growth
-8.3%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $39.0K | +77.3% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $22.0K | -31.3% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $32.0K | -39.6% | 2025-04-14, From 2023-01-01 |
| 2022-12-31 | $53.0K | -10.2% | 2024-07-03, From 2022-01-01 |
| 2021-12-31 | $59.0K | -1.7% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $60.0K | -17.8% | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | $73.0K | +19.7% | 2021-08-10, From 2019-01-01 |
| 2018-12-31 | $61.0K | n/a | 2021-01-25, From 2018-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $39.0K | +77.3% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $1.71M | -3.4% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $600.0K | +20.0% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $1.90M | -34.5% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $1.91M | +0.7% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $192.0K | -42.5% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $4.51M | +51.3% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $3.20M | -29.3% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $895.0K | +0.2% |
Compare EMMA, PRLD, EVMN, TNXP side by side · Screen every company in Pharmaceutical Preparations ↗